CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer.
EGFR Inhibitors Related Products:
Erlotinib; Erlotinib hcl; Gefitinib; AG-490; Dacomitinib; WZ4002; Pelitinib; Brigatinib analog; Allitinib; Rociletinib; Varlitinib; Icotinib; WHI-P154; AG-18; Nazartinib